Transfusion and Apheresis Science
Volume 42, Issue 1 , Pages 21-26 , February 2010

Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care

  • C. Stefanutti

      Affiliations

    • Plasmapheresis Unit, Department of Medical and Clinical Therapy, University of Rome ‘La Sapienza’, ‘Umberto I’, Hospital, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Clinical and Medical Therapy, Plasmapheresis Unit, University of Rome ‘La Sapienza’, ‘Umberto I’ Hospital, 155, Viale del Policlinico, I-00161 Rome, Italy. Tel.: +39 06 49970578; fax: +39 06 49972630.
    • ,
  • A. Vivenzio

      Affiliations

    • Plasmapheresis Unit, Department of Medical and Clinical Therapy, University of Rome ‘La Sapienza’, ‘Umberto I’, Hospital, Italy
    • ,
  • S. Di Giacomo

      Affiliations

    • Plasmapheresis Unit, Department of Medical and Clinical Therapy, University of Rome ‘La Sapienza’, ‘Umberto I’, Hospital, Italy
    • ,
  • B. Mazzarella

      Affiliations

    • Plasmapheresis Unit, Department of Medical and Clinical Therapy, University of Rome ‘La Sapienza’, ‘Umberto I’, Hospital, Italy
    • ,
  • P.M. Ferraro

      Affiliations

    • Renal Unit, Catholic University of the Sacred Heart of Rome, Rome, Italy
    • ,
  • S. Abbolito

      Affiliations

    • Department of Cardiology, University of Rome ‘La Sapienza’, Saint Andrew Hospital, Rome I-EU, Italy

Received 23 December 2008 ,Revised 11 February 2009 ,Accepted 9 March 2009.

References 

  1. Bewu AD, Durrington PN. Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis. 1990;85:1–14
  2. Bostom AG, et al. Lp(a): an independent CHD risk factor in men of the Framingham offspring cohort. JAMA. 1996;276:544–548
  3. Dahlen GH, et al. Associations of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758–764
  4. Amstrong VM, et al. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986;62:249–257
  5. Crouse JR. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis. 1996;7:321–326
  6. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis. 2000;10:247–251
  7. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994;14:1586–1593
  8. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106(12):1447–1452
  9. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic–hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85:350–353
  10. Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol. 1997;30:1491–1499
  11. Duriez P, Dallongeville J, Fruchart JC. Lipoprotein(a) as a marker for coronary heart disease. Br J Clin Pract. 1996;77A:54–61
  12. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis. 2002;48:1454–1459
  13. Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002;48:1454–1459
  14. Jaeger BR, Meiser B, Nagel D, et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 1997;96(9 Suppl.):II-154–II-158
  15. Dräger LJ, Julius U, Kraenzle K, et al. DALI – the first human whole blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest. 1998;28:994–1002
  16. Keller C. Indication of low-density lipoprotein apheresis in severe hypercholesterolemia and its vascular complications: dextran sulphate cellulose low-density lipoprotein apheresis. Ther Apher Dial. 2003;7(3):345–349
  17. Keller C. Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management. Ther Apher Dial. 2007;11(1):2–8
  18. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–97.
  19. Schettler V, Wieland E, Armstrong VW, et al. First steps toward the establishment of a German LDL-apheresis registry: recommendations for the indication and for quality management. Ther Apher. 2002;6:381–383
  20. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem. 2003;49(11):1785–1796
  21. Szczepiorkowski Zbigniew M, Bandarenko Nicholas, Kim Heawon C. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2007;22(3):106–175
  22. Thompson Gilbert R, Kitano Yuri. The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia. Ther Apher Dial. 2007;1(1):13–16
  23. Thompson GR HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247–255

PII: S1473-0502(09)00171-2

doi: 10.1016/j.transci.2009.10.003

Transfusion and Apheresis Science
Volume 42, Issue 1 , Pages 21-26 , February 2010

Article Tools

* Image Usage & Resolution